Alric Pierre, Hinchliffe Robert J, Wenham Peter W, Whitaker Simon C, Chuter Timothy A M, Hopkinson Brian R
Divisions of Vascular Surgery and Radiology, Nottingham University Hospital, Nottingham, United Kingdom.
J Vasc Surg. 2003 Feb;37(2):367-73. doi: 10.1067/mva.2003.75.
Endovascular repair (EVR) of abdominal aortic aneurysm (AAA) is being performed with increasing frequency worldwide. No studies have a complete follow-up of more than 4 years. Our study objective was to assess the long-term results and the durability of a first-generation stent graft with complete 7-year follow-up.
Between March 1994 and May 1995, 23 consecutive patients underwent treatment with the Chuter stent graft at a single center. All patients underwent computed tomographic scan before discharge, at 3 and 6 months, and annually thereafter. The data were prospectively collected on all patients. The median follow-up period was 72.5 months (range, 0.2 to 91 months). None of the patients were lost to follow-up.
Among these 21 men and two women with a median age of 69 years (range, 52 to 85 years), 11 (47.8%) were at high risk. The 30-day technical success rate was 87%. Acute (30-day) complications were one graft deployment failure (4.3%) that necessitated an immediate conversion, 20 intraoperative graft limb kinks (87%), all of which needed additional Wallstent (Schneider, Minneapolis, Minn) placement, four renal failures (17.4%), one type Ia endoleak complicated with AAA rupture (4.3%), and three perioperative deaths (13%). Late complications were eight type I or II endoleaks (34.8%) after a mean delay of 23.9 months (range, 3 to 69 months), 13 proximal stent migrations (56.5%) after a mean delay of 29.6 months (range, 7 to 58 months), six graft limb thromboses (26.1%) after a mean delay of 38.7 months (range, 3 to 71 months), one AAA rupture (4.3%), and 11 deaths (47.8%), with five AAA-related deaths (21.7%). The 3-year, 5-year, and 7-year cumulative endoleak rates were 34%, 41%, and 49%, respectively; the cumulative migration rates were 66%, 75%, and 75%, respectively; and the cumulative open surgery rates were 30%, 50%, and 50%, respectively. At the same intervals, the cumulative survival rates for any death were 69%, 56%, and 49%, respectively; the cumulative survival rates for AAA-related deaths were 82%, 82%, and 73%, respectively; and the cumulative secondary success rates were 54%, 28%, and 28%, respectively.
This studies emphasizes the need for close lifelong surveillance of AAAs treated with EVR. Despite the small population of this series, a long-term follow-up highlights that the first-generation homemade stent graft evaluated in this study failed to adequately protect the patient from AAA-related death and that most of the serious complications were related to a late failure of the aortic neck attachment. Better proximal fixation of the aortic stent graft is essential to improve the durability of EVR.
腹主动脉瘤(AAA)的血管腔内修复术(EVR)在全球范围内的实施频率日益增加。尚无研究对超过4年的情况进行完整随访。我们的研究目的是通过7年的完整随访来评估第一代支架型人工血管的长期效果和耐用性。
1994年3月至1995年5月期间,连续23例患者在单一中心接受了Chuter支架型人工血管治疗。所有患者在出院前、3个月和6个月时以及此后每年均接受计算机断层扫描。前瞻性收集了所有患者的数据。中位随访期为72.5个月(范围0.2至91个月)。无一例患者失访。
在这21名男性和2名女性患者中,中位年龄为69岁(范围52至85岁),其中11例(47.8%)为高危患者。30天技术成功率为87%。急性(30天)并发症包括1例移植物置入失败(4.3%),需立即改行开放手术;20例术中移植物肢体扭结(87%),均需额外置入Wallstent(施奈德公司,明尼阿波利斯,明尼苏达州);4例肾功能衰竭(17.4%);1例Ia型内漏合并AAA破裂(4.3%);3例围手术期死亡(13%)。晚期并发症包括8例I型或II型内漏(34.8%),平均延迟23.9个月(范围3至69个月);13例近端支架移位(56.5%),平均延迟29.6个月(范围7至58个月);6例移植物肢体血栓形成(26.1%),平均延迟38.7个月(范围3至71个月);1例AAA破裂(4.3%);11例死亡(47.8%),其中5例与AAA相关(21.7%)。3年、5年和7年的累积内漏率分别为34%、41%和49%;累积移位率分别为66%、75%和75%;累积再次手术率分别为30%、50%和50%。在相同时间间隔,任何原因导致的累积生存率分别为69%、56%和49%;与AAA相关的累积生存率分别为82%、82%和73%;累积二次成功率分别为54%、28%和28%。
本研究强调了对接受EVR治疗的AAA患者进行终身密切监测的必要性。尽管本系列研究样本量较小,但长期随访结果表明,本研究中评估的第一代国产支架型人工血管未能充分保护患者免于AAA相关死亡,且大多数严重并发症与主动脉颈部附着处的晚期失效有关。更好地实现主动脉支架型人工血管的近端固定对于提高EVR的耐用性至关重要。